Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 3Carcinoma, Squamous Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neoplasm Metastasis 1Mycosis Fungoides 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Head and Neck Neoplasms 1Carcinoma, Merkel Cell 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 3Taxes 3Radiotherapy 3Paclitaxel 3Cyclophosphamide 3Epirubicin 2Doxorubicin 2Docetaxel 2Biopsy 2trastuzumab biosimilar HLX02 1talimogene laherparepvec 1romidepsin 1pertuzumab 1pembrolizumab 1pegfilgrastim 1nintedanib 1neratinib 1grapiprant 1eribulin 1caficrestat 1bemcentinib 1Tamoxifen 1Razoxane 1Radiation 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Neoadjuvant Therapy 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inflammatory Breast Neoplasms × talimogene laherparepvec × Clear all
NCT02658812 2023-01-25

Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Terminated
11 enrolled 16 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡